Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v5-FR Version v1-EN
Language French English
Date Updated 2022-01-17 2021-11-30
Drug Identification Number 02491699 02491699
Brand name HYDROMORPHONE HYDROCHLORIDE INJECTION, USP HYDROMORPHONE HYDROCHLORIDE INJECTION, USP
Common or Proper name HYDROmorphone Hydrochloride Injection, USP 2 mg/mL SD Vial 1 mL HYDROmorphone Hydrochloride Injection, USP 2 mg/mL SD Vial 1 mL
Company Name FRESENIUS KABI CANADA LTD FRESENIUS KABI CANADA LTD
Ingredients HYDROMORPHONE HYDROCHLORIDE HYDROMORPHONE HYDROCHLORIDE
Strength(s) 2MG 2MG
Dosage form(s) SOLUTION SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR
Packaging size 1 mL 1 mL
ATC code N02AA N02AA
ATC description OPIOIDS OPIOIDS
Reason for shortage Delay in shipping of the drug. Delay in shipping of the drug.
Anticipated start date 2021-12-16 2021-12-16
Actual start date
Estimated end date 2022-01-14 2022-01-14
Actual end date 2022-01-14
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Fresenius Kabi Canada regrets to advise that due to a shipping delay, we will be encountering a supply interruption on our HYDROmorphone Hydrochloride Injection, USP 2 mg/mL SD Vial 1 mL effective December 16, 2021 until January 14, 2022. Sandoz is an alternate supplier of HYDROmorphone Hydrochloride Injection, USP and has been informed of our impending supply interruption. Fresenius Kabi Canada regrets to advise that due to a shipping delay, we will be encountering a supply interruption on our HYDROmorphone Hydrochloride Injection, USP 2 mg/mL SD Vial 1 mL effective December 16, 2021 until January 14, 2022. Sandoz is an alternate supplier of HYDROmorphone Hydrochloride Injection, USP and has been informed of our impending supply interruption.
Health Canada comments